Show simple item record

Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.

dc.contributor.author Holland, David P
dc.contributor.author Sanders, Gillian D
dc.contributor.author Hamilton, Carol D
dc.contributor.author Stout, Jason E
dc.coverage.spatial United States
dc.date.accessioned 2017-04-01T13:21:30Z
dc.date.available 2017-04-01T13:21:30Z
dc.date.issued 2011
dc.identifier https://www.ncbi.nlm.nih.gov/pubmed/21789248
dc.identifier PONE-D-11-06799
dc.identifier.uri https://hdl.handle.net/10161/13901
dc.description.abstract RATIONALE: Rifapentine-based regimens for treating latent tuberculosis infection (LTBI) are being considered for future clinical trials, but even if they prove effective, high drug costs may limit their economic viability. OBJECTIVES: To inform clinical trial design by estimating the potential costs and effectiveness of rifapentine-based regimens for treatment of latent tuberculosis infection (LTBI). METHODS: We used a Markov model to estimate cost and societal benefits for three regimens for treating LTBI: Isoniazid/rifapentine daily for one month, isoniazid/rifapentine weekly for three months (self-administered and directly-observed), and isoniazid daily for nine months; a strategy of "no treatment" used for comparison. Costs, quality-adjusted life-years gained, and instances of active tuberculosis averted were calculated for all arms. RESULTS: Both daily isoniazid/rifapentine for one month and weekly isoniazid/rifapentine for three months were less expensive and more effective than other strategies under a wide variety of clinically plausibly parameter estimates. Daily isoniazid/rifapentine for one month was the least expensive and most effective regimen. CONCLUSIONS: Daily isoniazid/rifapentine for one month and weekly isoniazid/rifapentine for three months should be studied in a large-scale clinical trial for efficacy. Because both regimens performed well even if their efficacy is somewhat reduced, study designers should consider relaxing non-inferiority boundaries.
dc.language eng
dc.publisher Public Library of Science (PLoS)
dc.relation.ispartof PLoS One
dc.relation.isversionof 10.1371/journal.pone.0022276
dc.subject Antitubercular Agents
dc.subject Cost-Benefit Analysis
dc.subject Drug Administration Schedule
dc.subject Humans
dc.subject Isoniazid
dc.subject Latent Tuberculosis
dc.subject Models, Biological
dc.subject Patient Compliance
dc.subject Rifampin
dc.subject Self Administration
dc.subject United States
dc.title Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.
dc.type Journal article
duke.contributor.id Holland, David P|0399367
duke.contributor.id Hamilton, Carol D|0045720
duke.contributor.id Stout, Jason E|0135823
pubs.author-url https://www.ncbi.nlm.nih.gov/pubmed/21789248
pubs.begin-page e22276
pubs.issue 7
pubs.organisational-group Basic Science Departments
pubs.organisational-group Biostatistics & Bioinformatics
pubs.organisational-group Clinical Science Departments
pubs.organisational-group Duke
pubs.organisational-group Duke Clinical Research Institute
pubs.organisational-group Faculty
pubs.organisational-group Institutes and Centers
pubs.organisational-group Medicine
pubs.organisational-group Medicine, Clinical Pharmacology
pubs.organisational-group Medicine, Infectious Diseases
pubs.organisational-group School of Medicine
pubs.publication-status Published
pubs.volume 6
dc.identifier.eissn 1932-6203
duke.contributor.orcid Stout, Jason E|0000-0002-6698-8176


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record